Author

E. L. Herzog

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:development & morphogenesis· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Ghincea· 1 shared B. Akosman· 1 shared C. G. Lee· 1 shared C. Perry· 1 shared C.-M. Lee· 1 shared H. Sun· 1 shared J. A. Elias· 1 shared J. H. Lee· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPathology

A. Ghincea

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Effect of Adrenalectomy on Bleomycin-Induced Pulmonary Fibrosis in Mice

J. McGovern, C. Perry, A. Ghincea, S. Shao, E. L. Herzog, H. Sun

This study investigates the effect of adrenalectomy on bleomycin-induced pulmonary fibrosis in mice, finding that adrenalectomy reduces lung remodeling but not collagen deposition.

bioRxiv · Jan 31, 2024Pathology

In vitro engineering of the lung alveolus

K. L. Leiby, Y. Yuan, R. Ng, M. S. B. Raredon, T. S. Adams, P. Baevova, K. K. Hirschi, S. G. Campbell, N. Kaminski, E. L. Herzog, L. E. Niklason

This study develops an in vitro strategy to engineer lung alveoli by coordinating biochemical, cellular, and mechanical cues to differentiate alveolar epithelial cells.

bioRxiv · Mar 13, 2022Bioengineering

Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis

J.-H. Lee, C.-M. Lee, J. H. Lee, M.-O. Kim, J. W. Park, S. Kamle, B. Akosman, E. L. Herzog, X. Y. Peng, J. A. Elias, C. G. Lee

This study identifies Kasugamycin as a novel CHIT1 inhibitor with strong antifibrotic effects in pulmonary fibrosis models.

bioRxiv · Feb 25, 2021Immunology